Navigation Links
New finding points to potential options for attacking stem cells in triple-negative breast cancer
Date:2/17/2014

ANN ARBOR, Mich. New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease.

The researchers identified a protein, SOCS3, that is highly expressed in normal cells but undetectable in triple-negative breast cancer. They showed that this protein is degraded in cancers, blocking the cellular off-switch of a feedback loop involving the inflammatory protein interleukin 6, IL6. When the switch does not get turned off, it enables cancer stem cells to grow.

"We have known for a long time known that there are important links between inflammation and cancer, including similar pathways that regulate normal and cancer stem cells," says study author Max S. Wicha, M.D., distinguished professor of oncology and director of the U-M Comprehensive Cancer Center.

"This work helps explain why these pathways shut off in normal tissues after injury but remain active in cancers, resulting in an increase in cancer stem cells. Furthermore, they suggest that blocking these inflammatory loops may be a means of targeting cancer stem cells, improving patient outcome," he says.

The study appears in the Nature journal Oncogene.

Currently, there are no molecularly targeted therapies aimed at triple-negative breast cancer, which is a type of cancer negative for estrogen receptor, progesterone receptor and the HER2 protein all key targets for current therapies. Patients with this form of disease tend to have worse outcomes.

The researchers tested a drug, bortezomib, in mouse models of triple-negative breast cancer and found that it stops the protein degradation, resulting in the inflammatory loop shutting off, which reduces the cancer stem cells, thereby blocking metastasis. Bortezomib is currently approved for treatment of the blood cancer multiple myeloma.

This team previously showed that IL6 can stimulate breast cancer stem cells in HER2-positive breast cancers and they are designing a clinical trial which uses an IL6 blocker. The new research suggests that adding bortezomib to the IL6 inhibitor may be a way to target stem cells in triple-negative breast cancer.

"Now that we unveiled how inflammation is regulated in triple-negative breast cancer, we expect that our studies can be translated into the clinic. The drugs used to block these chemical messengers are already approved for the treatment of rheumatoid arthritis and other inflammation-related diseases, which should facilitate their use in cancer," says study author Hasan Korkaya, Ph.D., assistant professor at the Georgia Regents University Cancer Center.

More laboratory testing is needed before a clinical trial can begin. The researchers also suspect that this pathway may apply to other cancers as well and are investigating that further.

Breast cancer statistics: 235,030 Americans will be diagnosed with breast cancer this year and 40,430 will die from the disease, according to the American Cancer Society


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related biology news :

1. Cell division finding could boost understanding of cancer
2. Finding Israels first camels
3. Findings point to potential treatment for virus causing childhood illnesses
4. Findings bolster fibers role in colon health
5. New breast cancer stem cell findings explain how cancer spreads
6. Spinal cord findings could help explain origins of limb control
7. Finding about classic suppressor of immunity points toward new therapies for bad infections
8. In surprise finding, blood clots absorb bacterial toxin
9. New finding shows that mother sharks home to their birthplace to give birth, like salmon and sea turtles
10. Great lakes waterfowl die-offs: Finding the source
11. Findings announced from landmark study on safety of adolescent bariatric surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New finding points to potential options for attacking stem cells in triple-negative breast cancer
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just ... software solution, LabKey Biologics . Built in collaboration with Just and designed ... Biologics provides drug research teams tools for biological entity registration, assay data integration, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... its brand-new, fully-certified hygienic SWB805 MultiMountTM weigh modules. These weigh modules are ... certified by National Sanitation Foundation (NSF). , As fully integrated weighing solutions, ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Harvill as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished ... and operations. , Avomeen is a leader in a wide range of ...
(Date:3/27/2017)... , March 27, 2017 Cousins Properties (NYSE: ... world,s leading biotechnology companies, has signed a 10-year, approximately 125,000 ... A office asset located in the Westshore submarket of ... thrilled that Amgen has chosen Corporate Center for their new ... Gellerstedt , president and chief executive officer of Cousins Properties. ...
Breaking Biology Technology: